Utilization patterns of antihypertensive drugs among the chronic kidney disease population in the United States: A cross-sectional analysis of the National Health and Nutrition Examination Survey

Clinical Therapeutics

Volumn 37, Issue 1, 2015, Pages 188-196

  Sonawane, Kalyani B ^a   Qian, Jingjing ^a   Hansen, Richard A ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Antihypertensive drugs; Chronic kidney disease; Medications acting on the renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RENAL PROTECTION; RETROSPECTIVE STUDY; UNITED STATES; CLINICAL PRACTICE; COMPLICATION; MIDDLE AGED; NUTRITION; RENAL INSUFFICIENCY, CHRONIC; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NUTRITION SURVEYS; PRACTICE PATTERNS, PHYSICIANS'; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84920808476     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.11.011     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2010. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2010.
2. Hoyert DL, Xu JQ. Deaths: Preliminary Data for 2011. Hyattsville, MD: National Center for Health Statistics; 2012.
3. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial. 2003;16:85-94.
4. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853-906.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. Feb 2002;39:S1-266.
6. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-290.
7. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
8. Wright JT Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
9. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
10. Hovind P, Rossing P, Tarnow L, et al. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int. 2001;60:277-283.
11. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
12. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
13. Sara fidis PA, Li S, Chen SC, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008;121:332-340.
14. Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insuffi ciency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55:441-451.
15. Sarafidis PA, Sharpe CC, Wood E, et al. Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease. Nephron Clin Pract. 2012;120:c147-c155.
16. De Nicola L, Minutolo R, Gallo C, et al. Management of hypertension in chronic kidney disease: the Italian multicentric study. J Nephrol. 2005;18:397-404.
17. Minutolo R, De Nicola L, Zamboli P, et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis. 2005;46:18-25.
18. Bailie GR, Eisele G, Liu L, et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20:1110-1115.
19. Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012;97:4605-4612.
20. Grant RW, Singer DE, Meigs JB. Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data. Clin Ther. 2005;27:773-781.
21. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD. http://www.cdc.gov/nchs/nhanes/nhanes-questionnaires.htm. Accessed September 20, 2013.
22. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med . 2009;150:604-612.
23. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. http://www.kidney.org/professionals/kdoqi/guidelines-ckd/p4-class-g1.htm. Accessed September 20, 2013.
24. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
25. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161:1207-1216.
26. Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation. 2006;113:213-221.
27. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
28. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180-188.
29. Nissenson AR, Collins AJ, Hurley J, et al. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12:1713-1720.
30. McClellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis. 1997;29:368-375.
31. Peralta CA, Hicks LS, Chertow GM, et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension. 2005;45:1119-1124.